SEARCH

SEARCH BY CITATION

References

  • 1
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899-909.
  • 2
    Schiller JH,Harrington D,Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 3
    Breathnach OS,Freidlin B,Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001; 19: 1734-1742.
  • 4
    Shepherd FA,Dancey J,Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 2095-2103.
  • 5
    Fossella FV,DeVore R,Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000; 18: 2354-2362.
  • 6
    Hanna N,Shepherd FA,Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 1589-1597.
  • 7
    Shepherd FA,Rodrigues Pereira J,Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
  • 8
    Wikstrand CJ,Bigner DD. Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha. J Natl Cancer Inst. 1998; 90: 799-801.
  • 9
    Veale D,Kerr N,Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993; 68: 162-165.
  • 10
    Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med. 2004; 55: 433-457.
  • 11
    Pavelic K,Banjac Z,Pavelic J, et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993; 13: 1133-1137.
  • 12
    Goldstein NI,Prewett M,Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995; 1: 1311-1318.
  • 13
    Ciardiello F,Damiano V,Bianco R, et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996; 88: 1770-1776.
  • 14
    Huang SM,Bock JM,Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 1935-1940.
  • 15
    Prewett M,Rothman M,Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 1998; 4: 2957-2966.
  • 16
    Kurai J,Chikumi H,Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007; 13: 1552-1561.
  • 17
    Ciardiello F,Bianco R,Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999; 5: 909-916.
  • 18
    Prewett MC,Hooper AT,Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002; 8: 994-1003.
  • 19
    Cunningham D,Humblet Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
  • 20
    Therasse P,Eisenhauer EA,Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006; 42: 1031-1039.
  • 21
    Vergniol JC,Bruno R,Montay G,Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr. 1992; 582: 273-278.
  • 22
    Robert F,Ezekiel MP,Spencer SA, et al. Phase I Study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001; 19: 3234-3243.
  • 23
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
  • 24
    Aapro M,Bruno R. Early clinical studies with docetaxel. Eur J Cancer. 1995; 31: S7-S10.
  • 25
    Extra JM,Rousseau F,Bruno R, et al. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res. 1993; 53: 1037-1042.
  • 26
    Bruno R,Hille D,Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998; 16: 187-196.
  • 27
    Ramlau R,Gervais R,Krzakowski M, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 2800-2807.
  • 28
    Hanna N,Lilenbaum R,Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5253-5258.
  • 29
    Giaccone G,Herbst RS,Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol. 2004; 22: 777-784.
  • 30
    Herbst RS,Giaccone G,Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol. 2004; 22: 785-794.
  • 31
    Gatzemeier U,Pluzanska A,Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 1545-1552.
  • 32
    Herbst RS,Prager D,Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
  • 33
    Van Cutsem E,Nowacki M,Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [abstract]. J Clin Oncol. 2007; 25( suppl). Abstract 4000.
  • 34
    Vermorken JB,Mesia R,Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 11161127.
  • 35
    Pirker R,Szczesna A,von Pawel J. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2008; 26( suppl 3). Abstract 3.
  • 36
    Lynch TJ,Dreisbach T,McCleod L, et al. A randomized multicenter phase III study of cetuximab (Erbitux) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC) [abstract]. J Thor Oncol. 2007; 2: S340. Abstract B3-03.
  • 37
    Hirsch FR,Herbst RS,Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non–small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008; 26: 3351-3357.
  • 38
    Wacker B,Nagrani T,Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in 2 large phase III studies. Clin Cancer Res. 2007; 13: 3913-3921.
  • 39
    Saltz L,Kies M,Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol. 2003; 22 ( suppl). Abstract 817.
  • 40
    Cohen EE,Rosen F,Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003; 21: 1980-1987.
  • 41
    Tejpar S,Peeters M,Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data [abstract]. J Clin Oncol. 2007; 25 ( suppl). Abstract 4037.
  • 42
    Sandler A,Gray R,Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.